| |
| |
| Exchange: |
Over The Counter |
| Security
Type: |
Common |
| Shares
Out: |
35,320,000 |
| Market
Cap: |
42.91(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.215 - $1.215 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cardiff Oncology is a clinical-stage, oncology therapeutics company, taking a medicine approach to target KRAS-mutated metastatic colorectal cancer, metastatic castrate-resistant prostate cancer and acute myeloid leukemia. Co.'s drug candidate, onvansertib, is an oral and highly-selective Polo-like Kinase 1 (PLK1) adenosine triphosphate competitive inhibitor. PLK1 is essential for regulating the cell division and maintaining genome stability in mitosis (cell division), spindle assembly, and DNA damage response. Co.'s intellectual property and proprietary technology enables it to analyze circulating tumor DNA and clinically actionable markers for predicting response to cancer therapies.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
30,000 |
52,950 |
280,950 |
| Total Buy Value |
$0 |
$41,100 |
$63,591 |
$443,027 |
| Total People Bought |
0 |
1 |
1 |
6 |
| Total Buy Transactions |
0 |
1 |
2 |
8 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Markin Rodney S |
Director |
– • – |
2018-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,667 |
22,610 |
|
- |
|
| Brancaccio John P |
Director |
– • – |
2018-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,667 |
43,167 |
|
- |
|
| Erlander Mark |
Chief Scientific Officer |
• – – |
2018-01-02 |
4/A |
D |
$0.00 |
$0 |
D/D |
(9,558) |
57,297 |
|
- |
|
| Erlander Mark |
Chief Scientific Officer |
• – – |
2018-01-02 |
4/A |
OE |
$0.00 |
$0 |
D/D |
18,750 |
66,855 |
|
- |
|
| Tennant Stanley |
Director |
– • – |
2017-09-05 |
4 |
S |
$0.69 |
$5,750 |
D/D |
(8,334) |
209,394 |
|
- |
|
| Jacob Gary S |
Director |
– • – |
2017-09-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,287 |
132,287 |
|
- |
|
| Tennant Stanley |
Director |
– • – |
2017-09-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,484 |
217,878 |
|
- |
|
| Adams Thomas Phd |
Director |
– • – |
2017-09-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,806 |
335,292 |
|
- |
|
| Billings Paul |
Director |
– • – |
2017-09-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,498 |
6,498 |
|
- |
|
| Markin Rodney S |
Director |
– • – |
2017-09-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,943 |
5,943 |
|
- |
|
| Brancaccio John P |
Director |
– • – |
2017-09-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,667 |
26,500 |
|
- |
|
| Erlander Mark |
Chief Scientific Officer |
• – – |
2017-09-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(12,928) |
48,051 |
|
- |
|
| Erlander Mark |
Chief Scientific Officer |
• – – |
2017-09-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
30,001 |
61,033 |
|
- |
|
| Welch William J |
CEO |
• • – |
2017-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
745,392 |
745,392 |
|
- |
|
| Erlander Mark |
Chief Scientific Officer |
• – – |
2017-01-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(23,968) |
31,032 |
|
- |
|
| Erlander Mark |
Chief Scientific Officer |
• – – |
2017-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,000 |
55,000 |
|
- |
|
| Tennant Stanley |
Director |
– • – |
2016-12-19 |
4 |
B |
$2.10 |
$21,000 |
D/D |
10,000 |
217,728 |
2.39 |
- |
|
| Welch William J |
CEO |
• • – |
2016-12-16 |
4 |
B |
$2.09 |
$9,944 |
D/D |
4,750 |
4,750 |
2.81 |
- |
|
| Tennant Stanley |
Director |
– • – |
2016-12-16 |
4 |
B |
$2.00 |
$29,932 |
D/D |
14,966 |
207,728 |
2.39 |
- |
|
| Erlander Mark |
Chief Scientific Officer |
• – – |
2016-12-14 |
4 |
B |
$2.08 |
$10,375 |
D/D |
5,000 |
5,000 |
2.74 |
- |
|
| Mignone Roberto |
10% Owner |
– – • |
2016-11-11 |
4 |
S |
$3.08 |
$993,214 |
I/I |
(322,472) |
2,968,115 |
|
- |
|
| Zaniboni Steve |
Former CFO |
• – – |
2016-04-21 |
4 |
OE |
$3.60 |
$275,866 |
D/D |
75,639 |
96,968 |
|
- |
|
| Posard Matthew L. |
Chief Commercial OfficerOffice |
• – – |
2015-08-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,000 |
|
- |
|
| Tennant Stanley |
Director |
– • – |
2015-08-12 |
4 |
B |
$6.06 |
$60,600 |
D/D |
10,000 |
192,762 |
2.39 |
- |
|
| Schuh Antonius |
CEO |
• • – |
2015-08-12 |
4 |
B |
$5.45 |
$109,000 |
D/D |
20,000 |
20,000 |
2.81 |
- |
|
108 Records found
|
|
Page 4 of 5 |
|
|
